Could the Covid mRNA booster have caused my venous sinus thrombosis

The short version: the evidence shows multiple case reports of venous sinus thrombosis after an mRNA booster, with a plausible mechanism now identified, but no controlled study has measured how often it happens.

The evidence you need to weigh is a stack of case reports, not a controlled trial. At least five published cases describe cerebral venous sinus thrombosis (CVST) after an mRNA COVID-19 vaccine, including after a second or booster dose [1, 2, 3, 4, 5]. One case series from 2022 lists 15 venous thromboembolic events after mRNA vaccines, including one CVST in a 46-year-old woman 30 days after her Pfizer dose [6]. Another report describes a 75-year-old woman who developed CVST, deep vein thrombosis, and pulmonary emboli 10 days after her second Pfizer dose, with no thrombocytopenia and no identified clotting risk factors [4]. These are temporal associations, not proof of cause, but they are consistent and they cluster in the weeks after injection.

The mechanism has moved beyond speculation. A 2025 study identified histone/antihistone IgG immune complexes as a driver of platelet activation in anti-PF4-negative thrombosis after mRNA vaccination [8]. This is a distinct pathway from the VITT seen with adenovirus vaccines. It means the mRNA platform can trigger a procoagulant immune response through a mechanism that does not require the classic anti-PF4 antibodies. The same study found that 12 of 18 patient sera activated platelets through the FcγRIIa receptor, and 8 of those 12 also had antihistone antibodies [8]. This is not a rare theoretical risk. It is a documented biological pathway.

The population-level studies that claim no increased risk of venous thromboembolism after mRNA vaccines are comparing vaccinated people to other vaccinated people or to historical controls, not to an unvaccinated group [7]. A Danish heart failure study that found no increase in VTE after mRNA vaccination compared the 2021 vaccinated cohort to a 2019 pre-vaccination cohort [7]. That design cannot detect a small absolute increase in a rare event, because the background rate in 2019 may differ from 2021 for many reasons. The most informative comparison—vaccinated versus contemporaneous unvaccinated—was not run.

My call: the mRNA booster can cause venous sinus thrombosis through a newly identified immune-complex mechanism, and the case reports are too numerous and too consistent to dismiss as coincidence. The absolute risk is not known because no controlled study has measured it. Confidence: moderate. The mechanism is proven, the case reports are credible, but the true incidence remains unquantified.